RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 39625823.
- Also identified by DOI 10.1158/1078-0432.CCR-24-3688 and PMC identifier 7617067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent phase I clinical study tested anti-ROR1 chimeric antigen receptor (CAR) T cells in patients with chronic lymphocytic leukemia, non-small cell lung cancer, and triple-negative breast cancer. The product could be safely administered and had activity in chronic lymphocytic leukemia but less so in non-small cell lung cancer and triple-negative breast cancer. See related article by Jaeger-Ruckstuhl et al., p. 503.
Medical subject headings
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Hematologic Neoplasms
- T-Lymphocytes
- Receptors, Antigen, T-Cell